Autologous Haematopoietic Stem Cell Transplantation and Systemic Sclerosis: Focus on Interstitial Lung Disease

Autologous hematopoietic stem cells transplantation (AHSCT) has been employed as treatment for severe systemic sclerosis (SSc) with high risk of organ failure. In the last 25 years overall survival and treatment-related mortality have improved, in accordance with a better patient selection and mobil...

Descripción completa

Detalles Bibliográficos
Autores principales: Bagnato, Gianluca, Versace, Antonio Giovanni, La Rosa, Daniela, De Gaetano, Alberta, Imbalzano, Egidio, Chiappalone, Marianna, Ioppolo, Carmelo, Roberts, William Neal, Bitto, Alessandra, Irrera, Natasha, Allegra, Alessandro, Pioggia, Giovanni, Gangemi, Sebastiano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909673/
https://www.ncbi.nlm.nih.gov/pubmed/35269465
http://dx.doi.org/10.3390/cells11050843
Descripción
Sumario:Autologous hematopoietic stem cells transplantation (AHSCT) has been employed as treatment for severe systemic sclerosis (SSc) with high risk of organ failure. In the last 25 years overall survival and treatment-related mortality have improved, in accordance with a better patient selection and mobilization and conditioning protocols. This review analyzes the evidence from the last 5 years for AHSCT-treated SSc patients, considering in particular the outcomes related to interstitial lung disease. There are increasing data supporting the use of AHSCT in selected patients with rapidly progressive SSc. However, some unmet needs remain, such as an accurate patient selection, pre-transplantation analysis to identify subclinical conditions precluding the transplantation, and the alternatives for post-transplant ILD recurrence.

Ejemplares similares